<DOC>
	<DOCNO>NCT02269475</DOCNO>
	<brief_summary>The study design gather efficacy , safety tolerability data Japanese child 7 18 year age would support approval MEDI3250 Japan .</brief_summary>
	<brief_title>A Phase3 Study Evaluate Efficacy Safety MEDI3250 Healthy Japanese Children Age 7 Years Through 18 Years</brief_title>
	<detailed_description>This randomize , double-blind , placebo control , multicenter study enrol 1008 subject . The study design gather efficacy , safety tolerability data Japanese child 7 18 year age would support approval MEDI3250 Japan . For child age 7 year 18 year , recommend dosage schedule intranasal administration 0.2 mL ( 0.1 mL per nostril ) . For child age 7 year 8 year previously vaccinate seasonal influenza , second dose give interval least 4 week . For efficacy endpoint , data gather incidence laboratory-confirmed influenza-like illness two treatment arm . Laboratory-confirmed influenza-like illness would include case influenza diagnose use culture-confirmation and/or PCR-based method . For safety tolerability endpoint , data gather solicited symptom , AEs SAEs . Subject randomize 2:1 receive MEDI3250 placebo .</detailed_description>
	<criteria>1 . Age 7 18 year age time randomization . 2 . A write informed consent obtain subject 's legally acceptable representative , write informed assent obtain subject possible . 3 . Available illness visit clinic influenza surveillance period . 4 . Ability legal representative understand comply requirement protocol． 5 . Parent/guardian available telephone , email etc． 6 . Females childbearing potential , unless surgically sterile ( ie , bilateral tubal ligation , bilateral oophorectomy , hysterectomy ) , sterile male partner , premenarchal , practice abstinence , must use effective method avoid pregnancy ( include oral , transdermal , implanted contraceptive , intrauterine device , female condom spermicide , diaphragm spermicide , cervical cap spermicide , use condom spermicide sexual partner ) 30 day prior first dose investigational product , must agree continue use precaution 60 day final dose investigational product . 7 . A subject consider investigator risk pregnancy must also negative urine pregnancy test screening , screen Day 0 occur day , day vaccination prior randomization . Investigator judgment require assess subject 's need pregnancy test . 8 . Healthy medical history physical examination OR presence stable underlie chronic medical condition hospitalization require previous year . 1 . Subjects previously administer influenza vaccine 20142015 influenza season 2 . Previous randomisation present study 3 . Participation another clinical study investigational product last 3 month 4 . Acute illness evidence significant active infection randomization ; 5 . Fever ≥99.5°F ( 37.5°C ) randomization ; 6 . Any drug therapy 15 day prior randomization expect drug therapy 28 day post last dose exception follow classes/types medication , allow : Contraceptives ( change contraceptive type method acceptable long guideline follow prevention pregnancy change ) ; Topical corticosteroid , calcineurin inhibitor , antifungal uncomplicated dermatitis ; Chronic medication ( include take asneeded basis ) well tolerate initiate and/or dosage change within 90 day prior randomization . 7 . Current expect receipt immunosuppressive medication within 28day window around dose , include immunosuppressive dose corticosteroid , define ≥20 mg/day prednisone equivalent , give daily alternate day ≥15 day ( intranasal , intraarticular , topical corticosteroid permit ) ; Note : topical corticosteroid uncomplicated dermatitis may use throughout study accord judgment investigator ; topical calcineurin inhibitor may use accordance package insert entry study participation . 8 . Any known immunosuppressive condition immune deficiency disease include know suspected infection human immunodeficiency virus ( HIV ) ; 9 . History allergic disease reaction likely exacerbate component investigational product include allergy egg , egg protein , gentamicin , gelatin serious , life threatening , severe reaction previous influenza vaccination ; 10 . Use aspirin salicylatecontaining medication within 28 day prior randomization expect receipt entire study ; 11 . History GuillainBarré syndrome ; 12 . Use antiviral agent activity influenza virus ( include amantadine , rimantadine , oseltamivir , zanamivir ) within 28 day prior first dose investigational product anticipate use agent study period ; 13 . Administration live virus vaccine within 30 day prior enrolment , receipt another live virus vaccine expect within 30 day study vaccination ; 14 . Administration inactivate vaccine within 14 day prior enrolment receipt another inactivate vaccine expect within 14 day study vaccination ; 15 . Receipt blood product within 90 day prior vaccination expect receipt study ; 16 . Pregnant lactate female 17 . Involvement plan conduct study ( applies AstraZeneca staff staff study site legal representative ) 18 . Any condition , opinion investigator , might interfere interpretation evaluation vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>MEDI3250</keyword>
	<keyword>Japanese child</keyword>
</DOC>